DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY

DMX-652Positive

AI Analysis

Summary

Dimerix acquired DMX-652, a Phase 2-ready asset for acute kidney injury treatment, with potential advancement into Phase 2 clinical studies under an open US IND application.

Clinical Trial Data

Phase

Phase 2

Importance:6/10

Sentiment:

0.70

pipeline expansionacquisitionPhase 2acute kidney injuryIND application

Related Companies

$RTSL

Read the original article

Published by PR Newswire Clinical Trials on July 17, 2026 11:00 AM

Read Original